Last updated on July 2013

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control UICC Stages II-IV)


Brief description of study

Efficacy and safety of a supportive treatment with European mistletoe extract Iscador® Qu ("quercus", i.e. from oak tree) in patients with colorectal cancer (Union for International Cancer Control, UICC stages II-IV), in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy) as compared to a parallel group with conventional therapy only. Primary Endpoints: Reduction of adverse effects of conventional therapy; reduction of therapy or disease induced symptoms (both are quality of life parameters and evaluated after 1 year); prolongation of disease free and/or overall survival (DFS, OS) after 5 years. Prospective observational confirmation study of previous retrospective cohort study. As this is a non-interventional cohort study, all therapies and measurements are performed on directive by the treating physician and/or request by the patient only.

Detailed Study Description

see summary

Clinical Study Identifier: NCT01448655

Contact Investigators or Research Sites near you

Start Over

Thomas Stein, MD

5th Med., Clinic Hietzing
Vienna, Austria
  Connect »

Leo Auerbach, Prof. MD

University Vienna
Vienna, Austria
  Connect »

Dirk Behringer, Prof. MD

Augusta Clinic
Bochum, Germany
  Connect »

Andrea Distelrath, MD

MVZ Fulda
Fulda, Germany
  Connect »

Thomas Seufferlein, Prof. M.D.

University Clinic - Internal Medicine I
Halle (Saale), Germany
  Connect »

Florian Glaser, MD

Hospital Herdecke, private University
Herdecke, Germany
  Connect »

Volker Heinemann, Prof. MD

Med. Clinic III, University Munich, Grosshadern
Munich, Germany
  Connect »

Eckhard Böcher, Prof. MD

Clinic Kloster Paradiese
Soest, Germany
  Connect »

Götz PL von Wichert, MD

Med 1, University Clinic Ulm
Ulm, Germany
  Connect »